Our products are patented in all key markets, including Australia, China, India, Japan, South Korea, Hong Kong SAR, Macau SAR, European Union (Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland), Canada, South Africa, New Zealand, Singapore, Malaysia, Vietnam and Indonesia, and have been allowed in USA and Israel.

The claims of the patents cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity. Additionally, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also provided.

Our patents strategy includes the use of the Patent Cooperation Treaty system with a view to obtain broad protection for our patent portfolio, which covers the WaferiX® technology, our products as well as potential new formulations. We aim to secure intellectual property protection for our invention and products in all relevant jurisdictions, as and when necessary. In most countries, the term awarded for a granted patent is 20 years from the date of application.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170